58 Multiple Myeloma Clinical Trials in Boston, MA (2026)

Q: How do I join a clinical trial in Boston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you.

Recruiting Multiple Myeloma Studies in Boston

NCT03689595Recruiting

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering ...

Boston, MA30,000 participantsDana-Farber Cancer Institute

View Study Details

NCT00898235Recruiting

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: Thi...

Boston, MA10,000 participantsBoston Medical Center

View Study Details

NCT02269592Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alteratio...

Boston, MA10,000 participantsDana-Farber Cancer Institute

View Study Details

NCT06615479Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple My...

Boston, MAPHASE3440 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06365060Recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is o...

Boston, MA400 participantsTufts Medical Center

View Study Details

NCT05137054Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studi...

Boston, MAPHASE1317 participantsRegeneron Pharmaceuticals

View Study Details

NCT04787042Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

Boston, MAPHASE1316 participantsSimcha IL-18, Inc.

View Study Details

NCT02343042Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/re...

Boston, MAPHASE1300 participantsKaryopharm Therapeutics Inc

View Study Details

NCT06952426Recruiting

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) pat...

Boston, MA300 participantsNovartis Pharmaceuticals

View Study Details

NCT05201781Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-te...

Boston, MAPHASE4295 participantsJanssen Research & Development, LLC

View Study Details

NCT07393282Recruiting

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who ...

Boston, MAPHASE3270 participantsRegeneron Pharmaceuticals

View Study Details

NCT05372354Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Mul...

Boston, MAPHASE1260 participantsBristol-Myers Squibb

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Boston, MAPHASE1246 participantsBeiGene

View Study Details

NCT06106945Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and prelimina...

Boston, MAPHASE1226 participantsAstraZeneca

View Study Details

NCT05862012Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM)....

Boston, MAPHASE1200 participantsIchnos Sciences SA

View Study Details

NCT06953960Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity o...

Boston, MAPHASE1199 participantsAbbVie

View Study Details

NCT06153251Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Boston, MAPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06121843Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants w...

Boston, MAPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06722235Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it ...

Boston, MAPHASE3171 participantsTakeda

View Study Details

NCT07116616Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM)....

Boston, MAPHASE1166 participantsModernaTX, Inc.

View Study Details

NCT05651932Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent...

Boston, MAPHASE1165 participantsK36 Therapeutics, Inc.

View Study Details

NCT07168499Recruiting

Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis

Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, immune-mediated disease characterized by recurrent episodes of relapse. The goal of thi...

Boston, MANA160 participantsMassachusetts General Hospital

View Study Details

NCT06948318Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making i...

Boston, MAPHASE3150 participantsTakeda

View Study Details

NCT04844606Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks ...

Boston, MAPHASE3150 participantsEli Lilly and Company

View Study Details

NCT06375044Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple ...

Boston, MAPHASE1130 participantsJiangsu Simcere Pharmaceutical Co., Ltd.

View Study Details

NCT06433947Recruiting

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in ...

Boston, MAPHASE1130 participantsOpna Bio LLC

View Study Details

NCT07115745Recruiting

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participan...

Boston, MAPHASE1125 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT07190196Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients wit...

Boston, MAPHASE3124 participantsSanofi

View Study Details

NCT06691217Recruiting

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coron...

Boston, MAPHASE2120 participantsMassachusetts General Hospital

View Study Details

NCT06140524Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that...

Boston, MAPHASE2116 participantsRegeneron Pharmaceuticals

View Study Details

NCT06817395Recruiting

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cogniti...

Boston, MA100 participantsMassachusetts General Hospital

View Study Details

NCT04508088Recruiting

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

The investigators will be evaluating bone marrow composition via magnetic resonance imaging in newly diagnosed adolescents with Crohn disease (CD) compared to healthy, matched controls. The investigat...

Boston, MA92 participantsMassachusetts General Hospital

View Study Details

NCT06232044Recruiting

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (...

Boston, MAPHASE188 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT06215118Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is e...

Boston, MAPHASE187 participantsPfizer

View Study Details

NCT06841705Recruiting

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

The goal of this clinical trial is to compare the effectiveness and safety of Vedolizumab with a short course of steroids compared to standard course of steroids for the treatment of immune checkpoint...

Boston, MAPHASE280 participantsShilpa Grover, MD, MPH

View Study Details

NCT05332639Recruiting

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

The aim of this study is to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for Crohn's disease (PRE-Crohn's) tool on behaviors and biomarkers associated wit...

Boston, MANA80 participantsMassachusetts General Hospital

View Study Details

NCT07075185Recruiting

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma....

Boston, MAPHASE170 participantsKelonia Therapeutics, Inc.

View Study Details

NCT07032818Recruiting

Adapted Hospital Discharge Intervention: the CONNECT Pilot

Hospital discharge is a dangerous time for patients: one in five will suffer an adverse event, such as a medication error, and nearly 25% will be readmitted within 30 days. This time is even more dang...

Boston, MANA60 participantsBoston Medical Center

View Study Details

NCT07007962Recruiting

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study...

Boston, MAPHASE360 participantsSanofi

View Study Details

NCT07104565Recruiting

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders....

Boston, MAPHASE256 participantsIncyte Corporation

View Study Details

NCT05469893Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. Peop...

Boston, MAPHASE252 participantsIrene Ghobrial, MD

View Study Details

NCT04331639Recruiting

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be...

Boston, MA50 participantsBoston Children's Hospital

View Study Details

NCT06655415Recruiting

Family Members At INcreased-risk for Developing Inflammatory Bowel Disease

First-degree relatives of people with inflammatory bowel disease ("IBD," including Crohn's disease and ulcerative colitis) have an increased risk for developing IBD themselves. This study will follow ...

Boston, MA50 participantsMassachusetts General Hospital

View Study Details

NCT05922501Recruiting

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The stud...

Boston, MAPHASE250 participantsMassachusetts General Hospital

View Study Details

NCT06518551Recruiting

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of...

Boston, MAPHASE149 participantsOmar Nadeem, MD

View Study Details

NCT05705024Recruiting

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of...

Boston, MAPHASE238 participantsUniversity of Illinois at Chicago

View Study Details

NCT06798012Recruiting

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over...

Boston, MAPHASE236 participantsTakeda

View Study Details

NCT06138275Recruiting

Elranatamab in R/R Multiple Myeloma

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma....

Boston, MAPHASE232 participantsMassachusetts General Hospital

View Study Details

NCT06832865Recruiting

ELISA in Relapsed/Refractory MM

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at leas...

Boston, MAPHASE230 participantsMassachusetts General Hospital

View Study Details

NCT05706766Recruiting

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologo...

Boston, MANA30 participantsDana-Farber Cancer Institute

View Study Details

NCT04614558Recruiting

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of...

Boston, MAPHASE227 participantsColumbia University

View Study Details

NCT07032714Recruiting

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Coh...

Boston, MAPHASE125 participantsMassachusetts General Hospital

View Study Details

NCT06799026Recruiting

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory M...

Boston, MAPHASE125 participantsDavid Avigan

View Study Details

NCT07377435Recruiting

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants w...

Boston, MAPHASE125 participantsDavid Avigan

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Boston, MAPHASE120 participantsAdaptimmune

View Study Details

NCT06083922Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including c...

Boston, MAPHASE220 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05020444Recruiting

TriPRIL CAR T Cells in Multiple Myeloma

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells....

Boston, MAPHASE118 participantsMarcela V. Maus, M.D.,Ph.D.

View Study Details

NCT07128355Recruiting

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatc...

Boston, MAEARLY_PHASE115 participantsMassachusetts General Hospital

View Study Details

About Multiple Myeloma Clinical Trials in Boston

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 58 multiple myeloma clinical trials recruiting participants in Boston, MA. These studies are seeking a combined 57,215 participants. Research is being sponsored by Dana-Farber Cancer Institute, Boston Medical Center, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and 33 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Boston — FAQ

Are there multiple myeloma clinical trials in Boston?

Yes, there are 58 multiple myeloma clinical trials currently recruiting in Boston, MA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 58 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 16, 2026 from ClinicalTrials.gov